Integrase strand transfer inhibitors in the management of HIV-positive individuals
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Integrase strand transfer inhibitors in the management of HIV-positive individuals
Authors
Keywords
-
Journal
ANNALS OF MEDICINE
Volume 46, Issue 3, Pages 123-129
Publisher
Informa UK Limited
Online
2014-03-03
DOI
10.3109/07853890.2014.883169
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dolutegravir
- (2014) M.A. Wainberg et al. DRUGS OF THE FUTURE
- Dolutegravir in antiretroviral-naive adults with HIV-1
- (2013) Hans-Jürgen Stellbrink et al. AIDS
- Impact of Primary Elvitegravir Resistance-Associated Mutations in HIV-1 Integrase on Drug Susceptibility and Viral Replication Fitness
- (2013) Michael E. Abram et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure
- (2013) Anne-Geneviève Marcelin et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- A Randomized Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate for Initial Treatment of HIV-1 Infection
- (2013) Andrew Zolopa et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- A Randomized, Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Coformulated Emtricitabine and Tenofovir DF for Initial Treatment of HIV-1 Infection
- (2013) Jürgen K. Rockstroh et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- A Randomized Phase 3 Study Comparing Once-Daily Elvitegravir With Twice-Daily Raltegravir in Treatment-Experienced Subjects With HIV-1 infection
- (2013) Richard Elion et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naive HIV-1–Infected Patients
- (2013) Jürgen K. Rockstroh et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
- (2013) Pedro Cahn et al. LANCET
- Dolutegravir for treatment of HIV: SPRING forwards?
- (2013) Laura J Waters et al. LANCET
- Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study
- (2013) Francois Raffi et al. LANCET
- Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial
- (2013) François Raffi et al. LANCET INFECTIOUS DISEASES
- Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials
- (2013) Joseph J Eron et al. LANCET INFECTIOUS DISEASES
- Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection
- (2013) Sharon L. Walmsley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure
- (2013) Thibault Mesplède et al. Retrovirology
- Raltegravir Pharmacokinetics in Treatment-Naive Patients Is Not Influenced by Race: Results from the Raltegravir Early Therapy in African-Americans Living with HIV (REAL) Study
- (2012) D. A. Wohl et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics and Pharmacodynamics of Once-Daily versus Twice-Daily Raltegravir in Treatment-Naïve HIV-Infected Patients
- (2012) Matthew L. Rizk et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Elvitegravir: a once-daily inhibitor of HIV-1 integrase
- (2012) Todd Wills et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Dolutegravir for the treatment of HIV
- (2012) Christine Katlama et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study
- (2012) Joseph J. Eron et al. JOURNAL OF INFECTIOUS DISEASES
- Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks
- (2012) Paul E Sax et al. LANCET
- Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial
- (2012) Edwin DeJesus et al. LANCET
- The structural biology of HIV-1: mechanistic and therapeutic insights
- (2012) Alan Engelman et al. NATURE REVIEWS MICROBIOLOGY
- Pharmacology of HIV integrase inhibitors
- (2012) Jessica L. Adams et al. Current Opinion in HIV and AIDS
- Resistance to HIV integrase inhibitors
- (2012) Thibault Mesplède et al. Current Opinion in HIV and AIDS
- HIV Drug Resistance and the Advent of Integrase Inhibitors
- (2012) Peter K. Quashie et al. Current Infectious Disease Reports
- Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults
- (2011) Sherene Min et al. AIDS
- Management of HIV infection in treatment-naive patients: A review of the most current recommendations
- (2011) S. D. Boyd AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- HIV-1 Integrase Inhibitor Resistance and Its Clinical Implications
- (2011) Jose-Luis Blanco et al. JOURNAL OF INFECTIOUS DISEASES
- Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir
- (2011) P. K. Quashie et al. JOURNAL OF VIROLOGY
- Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial
- (2011) Joseph J Eron et al. LANCET INFECTIOUS DISEASES
- Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study
- (2011) Jean-Michel Molina et al. LANCET INFECTIOUS DISEASES
- Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial
- (2011) Jan van Lunzen et al. LANCET INFECTIOUS DISEASES
- Development of Antiretroviral Drug Resistance
- (2011) Mark A. Wainberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacokinetics and Pharmacogenomics of Once-Daily Raltegravir and Atazanavir in Healthy Volunteers
- (2010) M. Neely et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroAntiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor
- (2010) Masanori Kobayashi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Long‐Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment‐Experienced Patients with Drug‐Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials
- (2010) Roy T. Steigbigel et al. CLINICAL INFECTIOUS DISEASES
- Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1–Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses
- (2010) Jeffrey L Lennox et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Raltegravir and Etravirine Are Active against HIV Type 1 Group O
- (2009) Verónica Briz et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
- Lack of a Clinically Important Effect of Moderate Hepatic Insufficiency and Severe Renal Insufficiency on Raltegravir Pharmacokinetics
- (2009) M. Iwamoto et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics and Safety of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor, in Healthy Volunteers
- (2009) S. Min et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Sustained Antiretroviral Effect of Raltegravir After 96 Weeks of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection
- (2009) Martin Markowitz et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
- (2009) Jeffrey L Lennox et al. LANCET
- Minimal Pharmacokinetic Interaction between the Human Immunodeficiency Virus Nonnucleoside Reverse Transcriptase Inhibitor Etravirine and the Integrase Inhibitor Raltegravir in Healthy Subjects
- (2008) M. S. Anderson et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection
- (2008) David A. Cooper et al. NEW ENGLAND JOURNAL OF MEDICINE
- Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection
- (2008) Roy T. Steigbigel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Integrase and integration: biochemical activities of HIV-1 integrase
- (2008) Olivier Delelis et al. Retrovirology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started